● Recruiting

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

Condition: Hepato Cellular Carcinoma (HCC) · Chemotherapy Effect · Sponsor: Linhui Peng

PhasePhase 3

Planned participants326

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).

This description comes directly from the study's public registry record.

Talk to the study team

Linhui Peng · 8613710591214 · penglinhui2927@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen Memorial Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07267806